Efficacy, safety and cost of new cardiovascular drugs: a survey
- 1 November 2003
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (8-9), 701-706
- https://doi.org/10.1007/s00228-003-0634-y
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Efficacy, safety and cost of new drugs acting on the central nervous systemEuropean Journal of Clinical Pharmacology, 2003
- Efficacy, safety, and cost of new anticancer drugsBMJ, 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- Choosing a Parenteral Anticoagulant AgentNew England Journal of Medicine, 2001
- Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.2000
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 1999
- Inconclusive messages from equivalence trials in thrombolysisHeart, 1999
- Platelet GPIIb-IIIa blockersThe Lancet, 1999
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996